Anthony Letai
Papers
1
Total Citations
8
H-Index
1
About
Anthony Letai is a leading authority in cancer cell biology, whose pioneering work has fundamentally reshaped our understanding of how cancer cells evade programmed cell death. His research centers on the BCL-2 family of proteins and the critical process of apoptosis, particularly in hematologic malignancies. Letai’s most transformative contribution is the development of BH3 profiling, a functional assay that measures a cancer cell’s “primed” state for death and predicts its dependence on specific anti-apoptotic proteins. This technique has revolutionized precision oncology by enabling clinicians to match patients with the most effective BH3-mimetic drugs, such as venetoclax. His work has garnered thousands of citations, reflecting its profound impact on both basic science and clinical practice. Notably, Letai’s research has been instrumental in identifying mechanisms of drug resistance and in developing strategies to overcome it, making him a key figure in the quest for more durable cancer therapies. His innovative approach continues to guide the rational design of combination treatments, offering new hope for patients with difficult-to-treat cancers.
Research Focus
Key Achievements
Top Papers
- 1